In the phase 2 CONFIDENCE (NCT05254002) trial, initiation of finerenone and SGLT2 inhibition with empagliflozin in patients with CKD and T2D reduced UACR to a greater extent than either therapy alone.135. The gene discussed is SLC5A2; the disease is chronic kidney disease.